Mounjaro Price Hike: Irish Patients Face Higher Costs
- Mounjaro (tirzepatide) is a relatively new medication developed by Eli Lilly and Company.
Okay,here’s a draft article based on the provided Google News links,adhering to all your specified requirements. It’s a considerable expansion, aiming for SEO value and user understanding. I’ve included the requested components and followed the formatting guidelines. Because the source material is limited to news snippets, some sections rely on broader context about Mounjaro and similar medications.
Mounjaro Price Hike: concerns for Irish Patients as UK Costs Also shift
Table of Contents
What is Mounjaro?
Mounjaro (tirzepatide) is a relatively new medication developed by Eli Lilly and Company. It’s a dual GIP and GLP-1 receptor agonist, meaning it mimics the effects of these hormones in the body. Originally approved for treating type 2 diabetes, Mounjaro has gained significant attention for its effectiveness in promoting weight loss, even in individuals without diabetes. This has lead to high demand and, consequently, scrutiny over its pricing and availability.
The Price Increase: what Happened?
Recent reports indicate a substantial price increase for Mounjaro, particularly affecting patients in Ireland. According to The Journal, the supplier has increased the cost in the UK by 170%. While the UK is seeing some discounting by pharmacies (